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Abstract: PURPOSE: The aim of this study was to examine predictors of ammonia exposure and hyper-
ammonemic crises in patients with urea cycle disorders. METHODS: The relationships between fasting
ammonia, daily ammonia exposure, and hyperammonemic crises were analyzed in >100 patients with
urea cycle disorders. RESULTS: Fasting ammonia correlated strongly with daily ammonia exposure (r
= 0.764; P < 0.001). For patients with fasting ammonia concentrations <0.5 upper limit of normal
(ULN), 0.5 to <1.0 ULN, and ￿1.0 ULN, the probability of a normal average daily ammonia value was
87, 60, and 39%, respectively, and 10.3, 14.1, and 37.0% of these patients, respectively, experienced ￿1
hyperammonemic crisis over 12 months. Time to first hyperammonemic crisis was shorter (P = 0.008)
and relative risk (4.5×; P = 0.011) and rate ( 5×, P = 0.006) of hyperammonemic crises were higher in
patients with fasting ammonia ￿1.0 ULN vs. <0.5ULN; relative risk was even greater (20×; P = 0.009)
in patients ￿6 years old. A 10- or 25-µmol/l increase in ammonia exposure increased the relative risk of a
hyperammonemic crisis by 50 and >200% (P < 0.0001), respectively. The relationship between ammonia
and hyperammonemic crisis risk seemed to be independent of treatment, age, urea cycle disorder subtype,
dietary protein intake, or blood urea nitrogen. Fasting glutamine correlated weakly with daily ammonia
exposure assessed as 24-hour area under the curve and was not a significant predictor of hyperammonemic
crisis. CONCLUSION: Fasting ammonia correlates strongly and positively with daily ammonia exposure
and with the risk and rate of hyperammonemic crises, suggesting that patients with urea cycle disorder
may benefit from tight ammonia control.
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INTRODUCTION
Urea cycle disorders (UCDs) are inborn errors of metabolism 
involving deficiencies of enzymes required for ureagenesis. 
They are manifested as acute and chronic hyperammonemia, 
and medical management is aimed at reducing ammonia con-
centrations through the restriction of protein intake and the 
use of alternative-pathway drugs to enhance excretion of waste 
nitrogen. Current UCD treatment guidelines indicate that 
ammonia should be kept within normal limits but otherwise 
provide limited guidance on the specific timing of blood draws 
or target levels.1
Glycerol phenylbutyrate (GPB; HPN-100, RAVICTI; 
Hyperion Therapeutics, Brisbane, CA) is a sodium- and sugar-
free ammonia-lowering agent that was approved in the United 
States in 2013 for UCD patients ≥2 years of age who cannot be 
managed by dietary protein restriction and/or amino acid sup-
plementation alone. The GPB clinical trials compared 24-hour 
ammonia concentrations during short-term steady-state dosing 
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Purpose: The aim of this study was to examine predictors of ammo-
nia exposure and hyperammonemic crises in patients with urea cycle 
disorders.
Methods: The relationships between fasting ammonia, daily ammo-
nia exposure, and hyperammonemic crises were analyzed in >100 
patients with urea cycle disorders.
Results: Fasting ammonia correlated strongly with daily ammonia 
exposure (r = 0.764; P < 0.001). For patients with fasting ammonia con-
centrations <0.5 upper limit of normal (ULN), 0.5 to <1.0 ULN, and 
≥1.0 ULN, the probability of a normal average daily ammonia value 
was 87, 60, and 39%, respectively, and 10.3, 14.1, and 37.0% of these 
patients, respectively, experienced ≥1 hyperammonemic crisis over 12 
months. Time to first hyperammonemic crisis was shorter (P = 0.008) 
and relative risk (4.5×; P = 0.011) and rate (~5×, P = 0.006) of hyper-
ammonemic crises were higher in patients with  fasting ammonia ≥1.0 
ULN vs. <0.5ULN; relative risk was even greater (20×; P = 0.009) in 
patients ≥6 years old. A 10- or 25-µmol/l increase in ammonia expo-
sure increased the relative risk of a hyperammonemic crisis by 50 and 
>200% (P < 0.0001), respectively. The relationship between ammonia 
and hyperammonemic crisis risk seemed to be independent of treat-
ment, age, urea cycle disorder subtype, dietary protein intake, or blood 
urea nitrogen. Fasting glutamine correlated weakly with daily ammo-
nia exposure assessed as 24-hour area under the curve and was not a 
significant predictor of hyperammonemic crisis.
Conclusion: Fasting ammonia correlates strongly and positively 
with daily ammonia exposure and with the risk and rate of hyper-
ammonemic crises, suggesting that patients with urea cycle disorder 
may benefit from tight ammonia control.
Genet Med advance online publication 11 December 2014
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with GPB or sodium phenylbutyrate (NaPBA) among 80 UCD 
patients aged 2 months to >70 years and studied longer-term 
outcomes, including hyperammonemic crises (HACs), among 
100 UCD patients, including 49 pediatric patients, treated with 
GPB for up to 1 year.
This report takes advantage of >1,000 prospectively collected 
timed blood samples to analyze correlates of daily ammonia 
exposure, assessed as 24-hour area under the curve, as well as 
the utility of ammonia and glutamine as predictors of HACs.
MATeRIALs AND MeTHODs
Clinical studies
Data from four short-term switchover (SO) studies and three 
12-month safety extension studies of adult and pediatric 
UCD patients were included in the analyses; all have been 
previously described. Protocols UP1204-003, HPN-100-
005SO, and HPN-100-012SO were short-term, open-label, 
fixed-sequence SO studies that evaluated ammonia control 
during equivalent dosing of GPB versus NaPBA.2–4 Study 
HPN-100-006 was a pivotal, randomized, double-blind, 
active-controlled, crossover study that established the nonin-
feriority of GPB to NaPBA as assessed by venous ammonia.5 
Most patients completing these protocols plus additional 
patients (a total of 100 patients, of whom 49 were pediatric) 
were enrolled into safety extension studies and received GPB 
for 12 months.5–7
All protocols and informed consents were reviewed and 
approved by the investigational review board of each partici-
pating institution before initiation. Eligible subjects had a con-
firmed or clinically suspected UCD and had been receiving 
NaPBA before enrollment. In all studies patients received GPB 
three times daily (or more frequently in small children to match 
their prior NaPBA schedule) at a daily dose equivalent to their 
previously prescribed NaPBA dose.
All procedures were in accordance with the ethical stan-
dards of the responsible committee on human experimentation 
(institutional and national) and with the Helsinki Declaration 
of 1975, as revised in 2000. Informed consent was obtained 
from all patients.
The ClinicalTrials.gov identifiers for the studies were 
NCT00551200, NCT00947544, NCT00947297, NCT00992459, 
and NCT01347073.
Ammonia and glutamine measurements
During the crossover studies, serial venous blood samples for 
ammonia analyses were collected over 24 hours after the patient 
had received 1–2 weeks of dosing (steady state) with either 
NaPBA or GPB. Samples for glutamine and ammonia were col-
lected after overnight (≥4–6 hours) fasting and before break-
fast and the first daily drug dose; additional ammonia samples 
were collected at 8, 12, and 24 hours after the dose for pediatric 
patients and approximately every 4 hours for adults. During the 
12-month studies, blood samples were collected monthly for 
ammonia and glutamine analyses, and information on HACs 
was recorded.
Baseline ammonia was defined as the screening or month 
0 value when the patient was taking NaPBA before receiving 
GPB. A HAC was defined as compatible clinical symptoms 
associated with one or more ammonia levels ≥100 µmol/l. 
Ammonia and HAC data were also collected retrospectively for 
up to 12 months before enrollment in each study while patients 
were receiving NaPBA. Ammonia and glutamine concentra-
tions were measured by an accredited hospital laboratory at 
each study site, and ammonia values were normalized to a stan-
dard range of 9–35 µmol/l.
statistical analyses
Short-term studies. Fasting ammonia concentrations were 
determined from the predose and 24-hour time points 
for steady-state measurements; maximum concentration 
represented the highest concentration determined during 
the 24-hour period. Ammonia 24-hour area under the 
concentration versus time curve from time 0 (predose) to 
24  hours (AUC0–24) was calculated using the linear trapezoid 
rule, and average daily ammonia was calculated as AUC0–24 
divided by time. The relationship between fasting ammonia 
and AUC0–24 was analyzed using logistic regression. Potential 
covariates examined included age, weight, drug type, and total 
daily dietary protein intake. Prediction intervals were calculated 
using standard least-squares methods and bootstrap methods.8 
Bootstrap intervals are less dependent on the observed data 
than standard intervals and therefore provide a more credible 
predication interval.
Fasting ammonia values were also divided into categories 
(<0.5, 0.5 to <1.0, and ≥1.0) relative to the upper limit of  normal 
(ULN). The probability that a patient whose fasting ammonia 
falls within a given category would have normal total daily 
ammonia exposure was modeled using generalized estimating 
equations assuming an exchangeable correlation structure and 
a logit link function. Confidence limits around the outcome 
probabilities were computed using the bootstrap method.8
Twelve-month studies. The time to the first HAC was deter-
mined by Kaplan–Meier analysis9 for the entire population, 
by age group, dichotomous age group, gender, and baseline 
ammonia ULN categories. Survival distributions between 
covariate values were computed using a log-rank test.10 Cox 
regression models were used to quantify the relative risk of time 
to first HAC.
The relationship between total ammonia exposure over time 
and the risk of HAC occurrence was explored by calculating 
time-normalized AUC for ammonia for patients with and 
without a HAC during the 12-month treatment with GPB. The 
AUC for ammonia, measured monthly, was calculated for each 
patient using the trapezoid rule over the course of the 12-month 
study. Time-normalized AUC was calculated by dividing AUC 
by the final study month of an ammonia assessment.
For the cumulative rate of HAC over 12 months, a negative 
binomial regression was performed with a flexible scale param-
eter to account for overdispersion of the HAC count data11; an 
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offset accounted for varying time in the study between patients. 
A multivariable negative binomial regression of HAC rate was 
also was developed to adjust for potential confounders.
A linear mixed regression model was used to analyze admis-
sion, peak, and discharge ammonia concentrations by patient 
characteristics. Log-transformed values were used for peak and 
discharge ammonia concentrations, and the model controlled 
for clustering of outcomes for patients who had more than one 
HAC.12 A generalized estimating equation logistic regression 
model was used to assess the association between the duration 
of the HAC and baseline ammonia values.13 Spearman corre-
lations were used to assess the relationship between baseline 
ammonia and glutamine concentrations.
ResULTs
The analyses included >1,000 ammonia results from 114 patients 
with UCD, including 100 patients (51 adult, 49 pediatric) in the 
12-month dosing protocols. Except for fasting ammonia, base-
line characteristics (age, gender, UCD subtype) were similar 
across baseline ammonia ULN categories, although there was 
a slightly higher proportion of patients aged 6–11 years in the 
0.5 to <1.0 ULN group than in the other two groups, and mean 
baseline glutamine values were slightly higher in the ≥1.0 ULN 
group than in the other ULN groups (Table 1).
short-term studies
Blood ammonia concentrations fluctuated considerably over 
24 hours; fasting ammonia values from morning blood draws 
exhibited the least variability (Supplementary Figure  S1 
online). There was a strongly positive and statistically  significant 
relationship between fasting ammonia and AUC0–24 (r = 0.764; 
P < 0.0001) (Figure 1). There was no discernable difference in 
the relationships observed with NaPBA and GPB treatment, so 
data for the two drugs were combined. None of the  potential 
covariates examined (e.g., age, weight, gender, and dietary 
protein) had a clinically or statistically significant impact on 
the model, and these covariates were not included in the final 
model.
When AUC and maximum daily ammonia concentra-
tion outcomes were modeled using ordered ULN categories, 
patients with a fasting ammonia <0.5 ULN had a greater like-
lihood of having a normal average daily ammonia value than 
patients with a fasting ammonia in other categories (inset in 
Figure 1).
Table 1 Patient characteristics in relation to baseline ammonia values
Variable
Baseline ammonia category
Total (N = 100)< 0.5 ULN (n = 39) 0.5–< 1.0 ULN (n = 34) ≥ 1.0 ULN (n = 27)
Mean age (SD), years 22.9 (17.7) 17.4 (15.0) 18.6 (12.8) 19.6 (15.9)
Age group, n (%)
  Adult (≥18 years old) 22 (56.4) 14 (41.2) 15 (55.6) 51 (51.0)
  Pediatric (<18 years old) 17 (43.6) 20 (58.8) 12 (44.4) 49 (49.0)
    <2 years old 3 (7.7) 2 (5.9) 2 (7.4) 7 (7.0)
    2–5 years old 7 (17.9) 4 (11.8) 5 (18.5) 16 (16.0)
    6–11 years old 5 (12.8) 10 (29.4) 2 (7.4) 17 (17.0)
    12–17 years old 2 (5.1) 4 (11.8) 3 (11.1) 9 (9.0)
Gender, n (%)
  Male 15 (38.5) 9 (26.5) 9 (33.3) 33 (33.0)
  Female 24 (61.5) 25 (73.5) 18 (66.7) 67 (67.0)
Fasting laboratory values, mean (SD)
  Ammonia (µmol/l) 11 (3.7) 30.8 (7.7) 51.9 (19.5) 28.80 (22.43)
  Glutamine (µmol/l) 694 (199.0) 710 (183.3) 857 (306.0) 743.4 (238.23)
  BUN (mmol/l) 3.4 (1.5) 2.5 (1.0) 2.5 (1.7) 2.8 (1.4)
UCD subtype, n (%)
  ARG 1 (2.6) 0 (0.0) 1 (3.7) 2 (2.0)
  ASL 7 (18.0) 5 (14.7) 1 (3.7) 13 (13.0)
  ASS 4 (10.3) 3 (8.8) 5 (18.5) 12 (12.0)
  CPS 1 (2.6) 0 (0.0) 0 (0.0) 1 (1.0)
  HHH 2 (5.1) 1 (2.9) 0 (0.0) 3 (3.0)
  OTC 24 (61.5) 25 (73.5) 20 (74.1) 69 (69.0)
12-month incidence of HAC
  Before taking NaPBA 0.433 0.389 1.071 0.581
  During study, taking GPB 0.135 0.150 0.711 0.288
ARG, arginase deficiency; ASL, argininosuccinate lyase deficiency; ASS, argininosuccinate synthase deficiency; BUN, blood urea nitrogen; CPS, carbonyl phosphate 
synthetase deficiency; GPB, glycerol phenylbutyrate; HAC, hyperammonemic crisis; HHH, hyperornithinemia–hyperammonemia–homocitrullinuria syndrome; NaPBA, sodium 
phenylbutyrate; OTC, ornithine transcarbamylase deficiency; UCD, urea cycle disorder; ULN, upper limit of normal.
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Twelve-month studies
Ammonia. Ammonia concentrations during up to 12 months 
of dosing were strongly related to baseline concentrations as 
categorized in relation to the ULN. Patients whose baseline 
ammonia was <0.5 ULN had mean monthly ammonia 
concentrations <35 µmol/l throughout the study, and their 
ammonia values showed less variability than did those among 
patients in the higher baseline ammonia categories (Figure 2, 
top panel). In the ammonia ≥1.0 ULN category, mean fasting 
ammonia decreased toward the normal range after approximately 
3 months of GPB treatment (Figure 2, top panel).
Thirty patients (30%) experienced a total of 54 HACs in 
the 12 months before starting GPB treatment, and 19 patients 
(19%) experienced a total of 27 HACs during 12 months of 
GPB treatment (Table 1). The proportion of patients experi-
encing a HAC increased in relation to baseline ammonia ULN 
categories (P = 0.0236) and was slightly higher for pediatric 
than for adult patients. Gender and UCD subtype had no 
effect on the rate of HACs. Mean (SD) baseline fasting ammo-
nia in patients with a HAC was 41.8 (23.7) µmol/l as compared 
with 25.7 (17.8) µmol/l in patients with no HAC (P = 0.0023).
The time to first HAC was significantly shorter (P = 0.0077) 
and the risk of HAC higher (4.5×; P = 0.011) in patients whose 
baseline ammonia was ≥1.0 ULN as compared with patients 
whose baseline ammonia was <0.5 ULN (Figure 2). After 
adjusting for age, gender, and race, patients with one or more 
baseline ammonia values ≥1.0 ULN had ~5.5 times the risk of 
having at least one HAC than patients with baseline ammonia 
<0.5 ULN (P = 0.005). When patients <6 years old at base-
line (who eat more frequently and for whom measurement 
of  fasting ammonia is problematic) were excluded from the 
 analysis, those with baseline ammonia values ≥1.0 ULN had an 
~20 times increase in the risk of having a HAC than patients 
with baseline ammonia <0.5 ULN (P = 0.009).
Figure 1  Correlation of fasting ammonia and daily ammonia exposure in short-term crossover studies (r = 0.764; P < 0.0001; N = 80). Bolded box 
indicates the normal range. Dashed lines represent 95% confidence intervals. Dotted boxes indicate fasting ammonia categories. Inset: probability of average 
daily ammonia being within normal limits by fasting ammonia upper limit of normal categories.
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The median time in the study was 361 days. The overall rate 
of HACs was 0.288 per patient per year, and the rate was sig-
nificantly higher among patients with baseline ammonia ≥1.0 
ULN than for those with baseline ammonia <0.5 ULN (0.711 
vs. 0.135/patient/year, respectively; P = 0.0057). Total ammonia 
exposure, calculated as time-normalized AUC during 12 months 
of GPB dosing, was significantly lower in patients who did not 
experience a HAC (23.6 vs. 35.0 µmol/l; P = 0.0006). The relative 
risk of experiencing a HAC increased by about 50 and 270%, 
respectively, for every 10 and 25 µmol/l increase in ammonia 
exposure (P < 0.0001) (Supplementary Figure S3 online).
The proportion of patients with baseline ammonia concen-
trations within each ULN category varied considerably among 
study sites (Figure 3, top panel), which therefore were grouped 
into three categories based on the percentage of patients enrolled 
whose baseline fasting ammonia was <0.5 ULN at baseline: group 
1 (6 study sites; 33 patients, of whom >50% had baseline ammo-
nia concentrations <0.5 ULN); group 2 (3 study sites; 29 patients, 
of whom 25–50% had baseline ammonia concentrations <0.5 
ULN); and group 3 (11 sites; 38 patients, of whom <25% had 
baseline ammonia concentrations <0.5 ULN) (Figure 3, bottom 
panel, and Supplementary Table S1 online). The proportion of 
patients who experienced a HAC was lowest (12%) among group 
1 sites and increased progressively to 21 and 24% in the group 2 
and 3 sites, respectively (Figure 3, bottom panel). Although the 
mean age of patients in group 3 was lower as compared with that 
in group 1 (14.7 vs. 24.5 years), other markers of disease severity, 
including the proportion of females with ornithine transcarba-
mylase deficiency and restriction of dietary protein, were similar 
among the groups.
Figure 3 Ammonia concentrations and hyperammonemic crisis rate by study site. Top panel: Percentage of patients at each study site with baseline 
ammonia <0.5 upper limit of normal (ULN), 0.5–1 ULN, and ≥1.0 ULN. Bottom panel: Percentage of patients in each ammonia ULN category by sites, grouped 
in relation to ammonia concentrations among patients enrolled at the site. Group 1 (6 study sites; 33 patients, of whom >50% had baseline ammonia 
concentrations <0.5 ULN); group 2 (3 study sites; 29 patients, of whom 25–50% had baseline ammonia concentrations <0.5 ULN); and group 3 (11 sites; 38 
patients, of whom <25% had baseline ammonia concentrations <0.5 ULN).
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During the 12-month GPB dosing protocols, HACs were 
generally of short duration; 48% resolved within 1 day and 64% 
resolved in <2 days. Most HACs were triggered by intercurrent 
illness and infection, and the most commonly reported clinical 
symptoms reported were vomiting (63%) and lethargy (37%), 
and other (48%) (Supplementary Table S2 online). Patients 
with baseline ammonia <1.0 ULN tended to have a higher like-
lihood of experiencing a HAC of <2 days’ duration than did 
patients with baseline ammonia ≥1.0 ULN (odds ratio, 3.06), 
but this difference was not statistically significant.
Glutamine. Monthly glutamine concentrations were generally 
higher in patients in the higher baseline ammonia ULN groups 
and, by 3 months of treatment, had decreased in the patients with 
the highest glutamine concentrations at baseline (Figure 4, top 
panel). However, there was no statistically significant difference 
between glutamine in patients with or without a HAC as assessed 
at baseline (782.4 vs. 732.0 µmol/l; P = 0.150), during the long-
term follow-up, or as total glutamine exposure (12–month time-
normalized AUC of 720.9 vs. 699.4 µmol/l*m; P = 0.686).
There were statistically significant but comparatively weak 
correlations between baseline ammonia and glutamine concen-
trations at the time of enrollment (r = 0.27; P = 0.008), as well as 
between fasting glutamine concentrations and daily ammonia 
exposure while taking GPB or NaPBA during the SO studies 
(r = 0.292, P < 0.001). However, when the relationship between 
glutamine and ammonia categories with respect to the ULN was 
analyzed, glutamine values varied substantially for patients in 
each category, and the overall correlation seemed to be driven 
by patients whose baseline ammonia exceeded 1.0 times the 
ULN (Figure 4). Patients with proximal deficiencies (ornithine 
transcarbamylase deficiency and carbonyl phosphate synthetase 
deficiency) showed a stronger correlation between  glutamine 
and ammonia (r = 0.56; P = 0.020; Supplementary Figure S2 
online). There was no correlation between baseline ammonia 
and UCD subtype or concentrations of either citrulline (r = 0.04; 
P = 0.414) or argininosuccinic acid (r = 0.14; P = 0.158).
DIsCUssION
Twenty-four-hour blood sampling in patients with UCD demon-
strated that blood ammonia concentrations fluctuated consider-
ably over 24 hours, even among the patients with comparatively 
stable and well-controlled UCD who were enrolled in these trials, 
making interpretation of random blood ammonia concentrations 
difficult. To identify the optimal timing of blood draws and a tar-
get level for ammonia in UCD patients, post hoc statistical analy-
ses of clinical trial data were conducted to assess the short-term 
relationship between fasting ammonia concentrations and daily 
ammonia exposure and the long-term relationship between fast-
ing ammonia concentrations and HACs in patients with UCDs.
Analysis of pooled data from the short-term studies showed a 
strong positive relationship between fasting ammonia and ammo-
nia AUC0–24. Because the wide prediction intervals observed with 
this analysis compromised the utility of individual levels for pre-
dicting daily ammonia exposure, the relationship between fasting 
ammonia concentrations categorized in relation to the ULN and 
the likelihood that a patient would have an average or maximal 
blood ammonia concentration within normal limits was modeled 
using generalized estimating equations. These analyses demon-
strated that fasting ammonia categorized in relation to the ULN 
(<0.5 ULN, 0.5 to <1.0 ULN, and ≥1.0 ULN) was strongly pre-
dictive of the likelihood that maximal and mean daily ammonia 
values would be within normal limits. This finding indicates that 
patients with fasting ammonia concentrations outside the normal 
range are likely being exposed to large amounts of ammonia dur-
ing the day, even if they do not exhibit any identifiable symptoms.
To further assess the importance of these correlations, 
data on ammonia, glutamine, and HACs collected during the 
12-month studies were analyzed using the patient groups by 
baseline ammonia ULN category. The relationship between 
Figure 4 Relationship between glutamine and ammonia concentra tions 
by baseline ammonia categories. Top panel: Glutamine concentrations 
during 12 months of glycerol phenylbutyrate treatment; mean (± SE) monthly 
glutamine concentrations by baseline ammonia upper limit of normal (ULN) 
category. Bottom panel: Scatterplot of baseline glutamine by ammonia ULN 
categories. The overall correlation between glutamine and ammonia was 
significant (r = 0.27; P = 0.008), whereas none of the correlations within the 
ammonia ULN categories was significant (r = 0.12, 0.18, and 0.12, respectively 
within the three ULN categories; P = nonsignificant for all).
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baseline ammonia ULN category and long-term outcome was 
demonstrated using several approaches. First, monthly ammo-
nia concentrations continued to be lowest in patients with base-
line ammonia concentrations <0.5 ULN and highest in patients 
with baseline ammonia ≥1.0 ULN. Second, the proportion 
of patients experiencing a HAC increased significantly with 
increasing baseline ammonia ULN category. Third, the time to 
first HAC was significantly shorter and the risk of HAC was sig-
nificantly greater in patients with baseline ammonia ≥1.0 ULN 
than in those with baseline ammonia <0.5 ULN. This associa-
tion between baseline ammonia and HAC risk was even more 
apparent when patients younger than 6 years of age at baseline 
(who feed more frequently and for whom true fasting ammonia 
concentrations are difficult to collect) were excluded from the 
analysis. Finally, the cumulative rate of HAC was more than five 
times higher for patients with baseline ammonia ≥1.0 ULN than 
for patients with baseline ammonia <0.5 ULN and was 20 times 
higher when patients younger than 6 years of age were excluded.
As is true for the relationship between fasting ammonia 
and daily ammonia exposure, the relationship between fast-
ing ammonia and HAC seems to be independent of treatment. 
Although fewer crises were experienced by patients dur-
ing treatment with GPB as compared with the prior year on 
NaPBA, the relationship between ammonia concentrations and 
the incidence of HACs was similar before beginning NaPBA 
treatment and subsequently during treatment with GPB.
The duration of HACs during GPB treatment was generally 
short, with more than 64% of crises lasting <2 days. Although 
ammonia values were generally higher in pediatric patients, there 
were no significant predictors for the admission, peak, or dis-
charge ammonia concentrations during a HAC or for the dura-
tion of a HAC.
Compared with ammonia, glutamine seems to be a weaker 
predictor of HAC. Although glutamine concentrations were 
higher at baseline in patients who experienced a HAC, there 
was no significant difference in glutamine between patients 
who did or did not experience a HAC during the study and no 
significant association between the rate of HAC and glutamine 
concentrations during the 12 months of dosing. Glutamine cor-
related modestly with fasting ammonia at baseline and decreased 
during GPB treatment in patients with the highest baseline glu-
tamine concentrations. Of interest, the correlation between 
fasting ammonia and glutamine seemed to be primarily driven 
by patients with the highest ammonia values, a finding similar 
to that reported by Maestri et al.14 based on multiple samples 
in a single patient with ornithine transcarbamylase deficiency. 
In addition, the relationship between ammonia and glutamine 
seemed to be strongest in patients with the proximal UCD sub-
types, ornithine transcarbamylase deficiency and carbonyl phos-
phate synthetase deficiency (Supplementary Figure S2 online), 
a finding that corroborates an earlier report by Wilson et al.15
Certain limitations of the current analyses deserve empha-
sis. First, although these timed ammonia and glutamine sam-
ples were collected prospectively, the analyses are post hoc. 
Second, the fact that lower fasting ammonia concentrations 
correlate strongly with lower average daily ammonia expo-
sure, as well as lower risk and frequency of HAC, could reflect 
intrinsic differences in disease severity; that is, patients with 
more severely deficient urea synthesis may exhibit both 
higher ammonia concentrations and increased susceptibil-
ity to crises with even minor triggering events. Two consid-
erations suggest an alternative explanation. First, baseline 
characteristics including age, gender, and UCD subtype were 
similar across these ULN groups. Second, data pertaining to 
ammonia concentrations and the frequency of HAC among 
patients enrolled at 20 sites in North America, even allowing 
for possible differences in adherence among patients at differ-
ent sites, seem to be better explained by different responses 
to management or differing management approaches rather 
than regional differences in the severity of illness. In any case, 
the findings should be interpreted with caution pending fur-
ther study and prospective validation.
The findings suggest that fasting ammonia is a reliable sur-
rogate for assessing adequacy of disease control; it correlates 
strongly with total daily ammonia exposure as well as HACs. 
They further suggest that even mildly elevated ammonia over 
long periods of time may put patients at risk of HAC and that 
patients with UCD, especially those ≥6 years old, may benefit 
from maintaining fasting ammonia concentrations <0.5 ULN. 
More frequent monitoring of fasting ammonia concentrations 
may require identifying certified clinical laboratories conve-
niently located for patients and/or further development of por-
table testing technology analogous to that in use for diabetes.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
ACKNOWLEDGMENTS
The authors gratefully acknowledge Richard Rowell (Hyperion) for 
his statistical review and thank the efforts of the study coordinators 
who made this study possible, including N. Schrager (Icahn School 
of Medicine at Mount Sinai); A. Donovan, J. Crawford, Pediatric TRU 
Staff; K. Defouw, J. Balliet (The Medical College of Wisconsin); M. 
Keuth, N. O’Donnell (Long Beach Memorial Hospital); M. Hussain, 
E. Bailey, A. Orton, M. Ambreen (The Hospital for Sick Children, Uni-
versity of Toronto, ON, Canada); C. Bailey, M.J. Dunkley (University 
of Utah); J. Perry, V. de Leon, A. Niemi, K. Cusmano (Stanford Uni-
versity); T. Carlson, J. Parker (University of Minnesota); S. Burr (Chil-
dren’s Hospital Colorado); K. Simpson (Children’s National Medical 
Center); K. Regis (Nationwide Children’s Hospital); A. Behrend, T. 
Marrone (Oregon Health & Science University); N. Dorrani (University 
of California, Los Angeles); C. Heggie (Case Western Reserve Uni-
versity); S. Mortenson (Maine Medical Center); S. Deward (Children’s 
Hospital of Pittsburgh); K. Bart, C. Duggan (SNBL); K. Murray, C. 
Dedomenico (Tufts Medical Center); C. Gross (University of Florida); 
L. Brody (Seattle Children’s Hospital); M. Mullins, S. Carter, A. Tran, 
J. Stuff, Texas Children’s Hospital General Clinical Research Center 
nursing staff (Baylor College of Medicine); Kathy Lisam (Hyperion); 
and UCD Consortium members, including Mark L. Batshaw, Men-
GeNeTICs in MeDICINe  |  Volume 17  |  Number 7  |  July 2015
568
LEE et al  |  Blood ammonia, glutamine, and hyperammonemic crises in patients with urea cycle disorders Original research article
del Tuchman, Matthias R. Baumgartner, Georg Hoffmann, Douglas 
S. Kerr, Margretta R. Seashore, Tamar Stricker, Susan Waisbren, and 
Mark Yudoff. The authors also acknowledge the Clinical and Trans-
lational Science Awards/General Clinical Research Center grants 
(Baylor College of Medicine, M01RR00188; Case Western Reserve 
University, NIDDK 1K08DK074573; Clinical and Translational Sci-
ence Institute at the Children’s National Medical Center, National 
Institutes of Health (NIH)/National Center for Research Resources, 
UL1RR31988; Medical College of Wisconsin, UL1RR31973; Mount 
Sinai School of Medicine, UL1RR29887; Oregon Health &  Science 
University, UL1RR24140; Stanford University, UL1RR25744; Tufts 
University, UL1RR25752; University of California, Los Angeles, 
UL1RR33176; University of Colorado, UL1RR25780; University 
of Florida, UL1RR29890; University of Minnesota, UL1RR33183; 
University of Pittsburgh, NIH, UL1TR000005; University of Utah, 
UL1RR25764; University of Washington, UL1TR000423), the Urea 
Cycle Disorders Consortium (NIH grant U54HD061221) and grants 
from the O’Malley Foundation, Kettering Fund, and Rotenberg 
Fund, which provided support. S.C. Nagamani is an awardee of the 
National Urea Cycle Disorders Foundation Research Fellowship and 
is supported by the Clinical Scientist Development Award from the 
Doris Duke Charitable Foundation. 
DISCLOSURE
M Mokhtarani, D.F.C., and B.F.S. are employees of Hyperion. 
None of the other authors has a financial interest in Hyperion, 
although  payments were made by Hyperion to each of the study 
sites for services provided in the conduct of the clinical studies on 
which these analyses were based, as well as to Accudata Solutions 
(D.A.M.) and M Marino for their assistance with the biostatistical 
 analyses. A.S. is a paid consultant to Hyperion. 
REFERENCES
 1. Berry GT, Steiner RD. Long-term management of patients with urea cycle 
disorders. J Pediatr 2001;138(suppl 1):S56–60; discussion S60-51.
 2. Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia 
scavenging agent with sodium phenylbutyrate in patients with urea cycle 
disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 
2010;100:221–228.
 3. Lichter-Konecki U, Diaz GA, Merritt JL 2nd, et al. Ammonia control in children 
with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate 
and glycerol phenylbutyrate. Mol Genet Metab 2011;103:323–329.
 4. Smith W, Diaz GA, Lichter-Konecki U, et al. Ammonia control in children ages 
2 months through 5 years with urea cycle disorders: comparison of sodium 
phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013;162:1228–34, 1234.e1.
 5. Diaz  GA, Krivitzky  LS, Mokhtarani  M, et al. Ammonia control and 
neurocognitive outcome among urea cycle disorder patients treated with 
glycerol phenylbutyrate. Hepatology 2013;57:2171–2179.
 6. Mokhtarani M, Diaz GA, Rhead W, et al. Elevated phenylacetic acid levels do 
not correlate with adverse events in patients with urea cycle disorders or hepatic 
encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. 
Mol Genet Metab 2013;110:446–453.
 7. Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment 
in children with urea cycle disorders: pooled analysis of short and long-term 
ammonia control and outcomes. Mol Genet Metab 2014;112:17–24.
 8. Davison A, Hinkley D. Bootstrap Methods and Their Application. Cambridge 
University Press: London, 1997.
 9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J 
Am Statist Assoc 1958;53:457–481.
 10. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Royal 
Statist Soc Series A (General) 1972:185–207.
 11. Breslow N. Tests of hypotheses in overdispersed Poisson regression and other 
quasi-likelihood models. J Am Statist Assoc 1990;85:565–571.
 12. Dean CB, Nielsen JD. Generalized linear mixed models: a review and some 
extensions. Lifetime Data Analysis 2007;13:497–512.
 13. Hardin JW. Generalized Estimating Equations (GEE). Wiley: Hoboken, NJ, 2005.
 14. Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a 
guide in the management of urea cycle disorders. J Pediatr 1992;121:259–261.
 15. Wilson CJ, Lee PJ, Leonard JV. Plasma glutamine and ammonia concentrations 
in ornithine carbamoyltransferase deficiency and citrullinaemia. J Inherit Metab 
Dis 2001;24:691–695.
  This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 
Unported License. The images or other third party material 
in this article are included in the article’s Creative Commons 
license, unless indicated otherwise in the credit line; if the 
material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder 
to reproduce the material. To view a copy of this license, visit 
http://creativecommons.org/licenses/by-nc-nd/3.0/
 Volume 17  |  Number 7  |  July 2015  |  GeNeTICs in MeDICINe
